Professor Andrew Spillane was elected to the BCT Board in July 2021 and is a member of the Finance, Risk and Audit Committee.

He is a Professor of Surgical Oncology at The University of Sydney. He specialises in the surgical management of breast cancer and melanoma. Professor Spillane is a senior VMO surgeon at the Mater North Sydney and Royal North Shore Hospitals.

He is a member of the BCT Scientific Advisory Committee and BCT Very Early Breast Cancer subgroup. He is past President of BreastSurgANZ and a board member / Deputy Chair of Melanoma and Skin Cancer (MASC) Trials (formerly the ANZMTG). He is a member of the BCNA Medical Advisory Committee and Faculty Member of Melanoma Institute Australia. Professor Spillane is Breast sub-editor for the ANZ Journal of Surgery, and an editorial board member of the Annals of Surgical Oncology and the Journal of Surgical Oncology. He is founding co-director and malignant disease unit of study co-ordinator of the University of Sydney’s Graduate Certificate in Advanced Breast Surgery.

Andrew’s research interests include neoadjuvant therapy, surgical clinical trials, promoting involvement of surgeons in multidisciplinary clinical trials, issues around quality assurance in surgery, and safe introduction of new surgical techniques and safe de-escalation of surgery. He is involved in clinical and translational research on aspects of breast cancer and melanoma research including trial management committee of the multiple international trials and a member of the International Neoadjuvant Melanoma Consortium. He has been an author on about 290 peer reviewed publications and co-authored 4 book chapters and chief investigator on multiple existing and recent NHMRC and MRFF grants.